Skip to content
CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • ASCO 2016 Update: Biomarker-Based Strategies

    Molecular clues may help predict patient treatment and outcomes.

    June 6, 2016| Arthur N. Brodsky, PhD
  • ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers

    Combination checkpoints, improved CAR T cells show promise.

    June 5, 2016| Arthur N. Brodsky, PhD
  • ASCO 2016 Update: The Value of Combination Immunotherapy

    Activating multiple immune pathways to improve patient outcomes.

    June 5, 2016| Arthur N. Brodsky, PhD
  • ASCO 2016 Update: The Personal Side of Immunotherapy

    To help more patients, treatments must get personal.

    June 4, 2016| Arthur N. Brodsky, PhD
  • ASCO 2016: The Year of Immunotherapy

    Chicago hosts top clinical cancer conference, immunotherapy shines.

    June 2, 2016| Arthur N. Brodsky, PhD
  • What Cancer Patients Should Know: Latest Immunotherapy News from ASCO

    Learn the latest news in cancer immunotherapy for melanoma, lung cancer, leukemia, liver cancer, and other cancer…

    June 5, 2015| CRI Staff
  • ASCO 2015: Report from Day 5

    The last day of the ASCO meeting featured talks on immunotherapy for pancreatic cancer, one the deadliest…

    June 2, 2015| Matthew Tontonoz
  • ASCO 2015: Report from Day 4

    More cancers prove treatable with checkpoint blockade therapy. Today: kidney, bladder, and ovarian cancer.

    June 1, 2015| Matthew Tontonoz
  • ASCO 2015: Report from Day 3

    Immunotherapy for brain cancer and the results of a large clinical trial for patients with advanced melanoma.

    May 31, 2015| Matthew Tontonoz
Previous Page
1 … 3 4 5 6
Next Page

Uniting for a World
Immune to Cancer

Stay Up To Date

Get Patient Stories & Research Updates


Donate By Mail

Cancer Research Institute
29 Broadway, Floor 4
New York, NY 10006-3111

Quick Links

  • Our Annual Impact
  • Blog
  • Careers
  • Contact Us
  • Donate

Trusted & Top-Rated charity

Charity Navigator
Candid Platinum Transparency 2026
Charity Watch Top Rated
BBB Accredited Business

connect with Us

LinkedIn icon
Facebook Icon
X icon
Instagram icon
YouTube icon

The Cancer Research Institute is a 501(c)(3) charitable organization. Our Federal Tax ID Number is 13-1837442.

©2026 Cancer Research Institute

*Immunotherapy results may vary from patient to patient.

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
Trigger Donate Modal